PDFAMS¥Ä-¥ë ¥ê¥ê-¥¹Í½Äê

PDFAMS¤Ë¤è¤ëÊ£¿ô¤Î¥â¥Ç¥ë¤«¤é¤ÎºÇÎÉ¥â¥Ç¥ë¼«Æ°È½ÊÌ¥Ä-¥ë

2006ǯ²Æ¤Ë³«ºÅ¤µ¤ì¤Þ¤·¤¿¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬¤Î¹ñºÝ¥³¥ó¥Æ¥¹¥ÈCASP7(Critical Assessment of Techniques for Protein Structure Prediction)¤Ë¤ª¤¤¤Æ¡¢³ô¼°²ñ¼Ò¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÇß»³¶µ¼ø¤Ï¡¢200¤òͤ¨¤ë»²²Ã¥°¥ë¡¼¥×¤ÎÃæ¤ÇÀ¤³¦ºÇ¹â¥ì¥Ù¥ë¤ÎÀ®ÀÓ¤ò¤ª¤µ¤á¤Þ¤·¤¿¡£
¤½¤ÎCASP7¤Ç¿¿ô¤Î¥â¥Ç¥ë¤«¤éºÇŬ¤Ê¥â¥Ç¥ë¤òÁª¤Ó½Ð¤·¡¢Ãø¤·¤¯¥â¥Ç¥ë¤ÎÀºÅÙ¤ò¸þ¾å¤µ¤»¤ë¤³¤È¤ËÀ®¸ù¤·¤¿¥¯¥¦¥©¥ê¥Æ¥£¡¼¥¢¥»¥¹¥á¥ó¥È¥×¥í¥°¥é¥à(CIRCLE)¤òPDFAMS¤ËÁȹþ¤ß¤Þ¤·¤¿¡£
PDFAMS¤ÈƱÍͤËFASTA·Á¼°¤Ç¥¢¥ß¥Î»ÀÇÛÎó¤òÆþÎϤ·¤Þ¤¹¤È¡¢³Æ¼ï¥¢¥é¥¤¥á¥ó¥È¥Ä¡¼¥ë(PDFAMS¤Ç¤ÏPDB 95% NR¤ËÂФ¹¤ëRPS-BLAST¤À¤±¤Ç¤¹¤¬¡¢PDB 95% NR¡¢Pfam¡¢NCBI NR¤Ê¤É¤Î¥Ç-¥¿¥Ù-¥¹¤ËFASTA¡¢BLAST¡¢PSI-BLAST¡¢IMPALA¡¢PSI-PRED¤òÁȤ߹ç¤ï¤»¤Æ¼Â¹Ô)¤«¤éÆÀ¤é¤ì¤ë¥¢¥é¥¤¥á¥ó¥È¥Ç-¥¿¤ÎÃæ¤«¤é¡¢PDFAMS¤ÇÍ­°Õ¤Ê¿ô¤À¤±¥â¥Ç¥ê¥ó¥°¤ò¤·¤¿¤Î¤Á¡¢CIRCLE¤Ç¤½¤ì¤é¥â¥Ç¥ë¤Î½ç°ÌÉÕ¤±¤ò¤Ë¹Ô¤¤¡¢ºÇÎɤΥâ¥Ç¥ë¹½Â¤¤¬¤É¤ì¤«¤òõ¤·¤À¤¹µ¡Ç½¤òÍ­¤¹¤ë¥Ä-¥ë¤Ç¤¹¡£
ËÜ¥Ä-¥ë¤Ë¤´´Ø¿´¤¬¤¢¤ê¤Þ¤¹Êý¤Ï¡¢¤ªÌ䤤¹ç¤ï¤»¥Õ¥©-¥à¤«¤é¤ª´ê¤¤¤¤¤¿¤·¤Þ¤¹¡£

CASP7¤Î·ë²Ì¡¢CIECLE¤Î¾ÜºÙ:
Proteins, 69, Suppl 8, 98-107 (2007)
ÆÃµö½Ð´ê2006-316356¸½Ì¤¸ø³«


ProteinDiscovery¤Î¤´¾Ò²ð

-¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬µ»½Ñ¤ò´ðÈפË-

ÁÏÌô¤ò¹Ô¤¦¤Ë¤¢¤¿¤ê¡¢¥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¤òÃΤ뤳¤È¤ÏɬÍ×ÉԲķç¤Ç¤¹¡£ ¤·¤«¤·¡¢°ìÈ̤˥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¤òÀºÅÙÎɤ¯µá¤á¤ë¤³¤È¤ÏÈó¾ï¤Ëº¤Æñ¤Ç¡¢ ¤«¤Ä½ÏÎý¤òÍפ¹¤ëºî¶È¤È¤Ê¤ê¤Þ¤¹¡£
ÊÀ¼Ò¤Ç¤ÏËÌΤÂç³ØÌô³ØÉôÇß»³½¨ÌÀ¶µ¼ø¤òÃæ¿´¤ËÇݤï¤ì¤¿´ðÈ×µ»½Ñ¤ò³è¤«¤·¤¿ ProteinDiscoveryÀ½ÉÊ·²¤Î³«È¯¡¦ÈÎÇ䡦¥µ¥Ý¡¼¥È¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£ ¤½¤ÎÃæ³Ë¤òô¤¦¤Î¤¬¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Í½Â¬¥Ä¡¼¥ëPDFAMS¥·¥ê¡¼¥º ¥½¥Õ¥È¥¦¥§¥¢¤Ç¤¢¤ê¡¢ ÍÍ¡¹¤Ê¥ª¥×¥·¥ç¥ó¥â¥¸¥å¡¼¥ë¤òÄɲ乤뤳¤È¤Ç ¿ºÌ¤Êµ¡Ç½¤äÀ¤³¦¥È¥Ã¥×¥ì¥Ù¥ë¤Îͽ¬ÀºÅÙ¤ò¼Â¸½¤¹¤ë¤³¤È¤¬²Äǽ¤Ç¤¹¡£ ¤½¤ÎÀ®²Ì¤Î°ìü¤È¤·¤Æ¡¢¿··¿ÇÙ±ê¤Ç¤¢¤ë½Å¾ÉµÞÀ­¸ÆµÛ´ï¾É¸õ·²SARS¤Î¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¤òͽ¬¤¹¤ë¤³¤È¤ËÀ®¸ù¤·¡¢À¤³¦¤ËÀè¶î¤±¤Æ¥â¥Ç¥ë¹½Â¤¤ò¸ø³«¤·¤Æ¤¤¤Þ¤¹¡£
Rep
PDFAMS¥·¥ê¡¼¥º ¥½¥Õ¥È¥¦¥§¥¢¤Ë¤è¤êͽ¬¤µ¤ì¤¿SARS¥¦¥£¥ë¥¹¤ÎRNA PolymeraseΩÂι½Â¤ <,tr>
¤¿¤À¤¤¤ÞSARS¥¿¥ó¥Ñ¥¯¼Á¹½Â¤¤ò̵½þÄó¶¡Ã桪

¿·Ãå¾ðÊó

2008ǯ6·î23Æü 6·î20Æü(¶â)¤ËËÌΤÂç³ØÌô³ØÉô¥³¥ó¥Ù¥ó¥·¥ç¥ó¥Û¡¼¥ë¤Ë¤ª¤¤¤Æ¡Ö¹½Â¤³èÀ­¥Õ¥©¡¼¥é¥à2008¡ÔɸŪÃÁÇò¼Á»Ö¸þ¤Î¥±¥ß¥«¥ë¥Ð¥¤¥ª¥í¥¸¡¼¤È¹½Â¤³èÀ­Áê´Ø¡Õ¡×¤¬³«ºÅ¤µ¤ì¡¢ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÌô³ØÉôÇß»³½¨ÌÀ¶µ¼ø¤¬¡Ø¹âǽΨ¥¤¥ó¥·¥ê¥³¥Ñ¥¤¥×¥é¥¤¥ó¸¦µæ¤È¥É¥Ã¥­¥ó¥°°åÌôÉʸôÊä²½¹çʪ¤ÎÁªÂò¡Ù¤Î±éÂê¤Ç¹Ö±é¤·¤Þ¤·¤¿¡£New!
2008ǯ5·î2Æü ¤ªÌ䤤¹ç¤ï¤»¤ËÂФ¹¤ë¤ªÅú¤¨¡§¤É¤Î¤è¤¦¤Ë¥¢¥ß¥Î»ÀÃÖ´¹¤ò¹Ô¤Ê¤¨¤Ð¡¢¤è¤ê¹â¤¤À¸Íý³èÀ­¤ò¤â¤Ä¥¿¥ó¥Ñ¥¯¼Á¤¬Í½Â¬¤Ç¤­¤½¤¦¤«¡£New!
2008ǯ4·î26Æü ¥¿¥ó¥Ñ¥¯¼Á¤Î´ð¼ÁÃÖ´¹¤ò£±»Ä´ðÃÖ´¹¤Ë¤è¤Ã¤Æ¹Ô¤Ê¤¦ÊýË¡¤ò³«»Ï¤¤¤¿¤·¤Þ¤·¤¿¡£
2008ǯ4·î26Æü ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤¬½Ð´ê¤·¤Æ¤¤¤ëÆÃµö¤ò¸ø³«¤¤¤¿¤·¤Þ¤·¤¿¡£
2008ǯ4·î25Æü ¥¿¥ó¥Ñ¥¯¼Á¤Î£±»Ä´ðÃÖ´¹¤ò¼«Í³¥¨¥Í¥ë¥®¡¼¤Î°ÂÄê²½¤ò»ØÉ¸¤È¤·¤Æ¥ê¥¹¥È¥¢¥Ã¥×¤¹¤ë¥Ó¥¸¥Í¥¹¤ò»Ï¤á¤Þ¤·¤¿¡£Choline dehydrogenase, mitochondrial precursor (CHD)¤òÎã¤Ë¼«Í³¥¨¥Í¥ë¥®¡¼¤Î°ÂÄê¤Ê£±»Ä´ðÃÖ´¹¥¿¥ó¥Ñ¥¯¼Á¤ÎÁÏÀ½¤òͽ¬¤·¤Æ¤¤¤Þ¤¹¡£
2008ǯ4·î23Æü ÆÃ´ê2002-547051¥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¹½ÃÛÊýË¡(WO2002/044954 ÆüËܤΤܹ߰Ô)¤¬ÆÃµöººÄꤵ¤ì¤Þ¤·¤¿¡£
2008ǯ4·î22Æü Ê¿À®20ǯ6·î20Æü(¶â)ËÌΤÂç³ØÌô³ØÉô¥³¥ó¥Ù¥ó¥·¥ç¥ó¥Û¡¼¥ë¤Ç¹½Â¤³èÀ­¥Õ¥©¡¼¥é¥à2008¡ÖɸŪÃÁÇò¼Á»Ö¸þ¤Î¥±¥ß¥«¥ë¥Ð¥¤¥ª¥í¥¸¡¼¤È¹½Â¤³èÀ­Áê´Ø¡×¤¬³«ºÅ¤µ¤ì¤Þ¤¹¡£¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Îµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÇß»³½¨ÌÀËÌΤÂç³ØÌô³ØÉô¶µ¼ø¤¬¡Ö¹âǽΨ¥¤¥ó¥·¥ê¥³¥Ñ¥¤¥×¥é¥¤¥ó¸¦µæ¤È¥É¥Ã¥­¥ó¥°°åÌôÉʸôÊä²½¹çʪ¤ÎÁªÂò¡×¤Î±éÂê¤Ç¹Ö±é¤·¤Þ¤¹¡£
2008ǯ4·î18Æü Purdue University¤ÎÌÚ¸¶Âçμ¶µ¼ø¤é¤¬ºîÀ®¤·¤¿ÂçIJ¶Ý¤Î¥¿¥ó¥Ñ¥¯¼Á¥â¥Ç¥ë¥Ç¡¼¥¿¥Ù¡¼¥¹(¥â¥Ç¥ê¥ó¥°¤ËPDFAMS¤ò»ÈÍÑ)¤¬¸ø³«¤µ¤ì¤Þ¤·¤¿¡£º¸Â¦¥³¥ó¥È¥í¡¼¥ë¥Ñ¥Í¥ë¤ÎEcoliPredict¥Ü¥¿¥ó¤«¤éÆþ¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£¤Ê¤ª´Êñ¤Ê¥Ç¡¼¥¿¥Ù¡¼¥¹¤ÎÀâÌÀ¤¬¡¢EcoliPredict¥È¥Ã¥×¥Ú¡¼¥¸¤Ë¤¢¤ëAbout EcoliPredict¤ò¤´Í÷¤¯¤À¤µ¤¤¡£
2008ǯ4·î11Æü ËÌΤÂç³ØÌô³ØÉô£³Ç¯À¸¤Î¡Öʬ»Ò¤ÎΩÂι½Â¤¤ÈÀ¸Ì¿¡×¤Î¹ÖµÁ¥Î¡¼¥È¤ò½ç¼¡·ÇºÜ¤·¤Þ¤¹¡£PDFAMS¤Ç¥â¥Ç¥ê¥ó¥°¤·¤¿¥¿¥ó¥Ñ¥¯¼Á¤È¥É¥é¥Ã¥°Ê£¹çÂΤΥâ¥Ç¥ë¤ÈChooseLD(ÆÃ´ê2007-293751¡¢11·î12Æü½Ð´ê)¤ò»È¤Ã¤ÆÆÀ¤é¤ì¤¿¡¢¥Õ¥§¡¼¥ºII¤äIII¤ÎÌôʪ¤È¤½¤ì¤é¼õÍÆÂΤȤÎ̤ȯɽ¤Î¥É¥Ã¥­¥ó¥°Áê¸ßºîÍѹ½Â¤¤¬¼¡¡¹¤È¸ø³«¤µ¤ì¤Æ¤¤¤­¤Þ¤¹¡£º¸Â¦¤Î¥á¥Ë¥å¡¼¤«¤é¤ªÆþ¤ê¤¯¤À¤µ¤¤
2008ǯ4·î2Æü ¾¾ÌÚ¶¯¤¬¼èÄùÌò¤ò¼­Ç¤¤·¡¢ã·Æ£ÃÒ¤¬¼èÄùÌò¤Ë½¢Ç¤¤·¤Þ¤·¤¿
2008ǯ3·î21Æü "Dynamic interaction among the platform and two membrane-proiximal immunoglobulin-like domain of class I major histocompatibility complex: normal mode analysis" ¤Î¸¦µæ¤¬ Chem.Pharm.Bull.,Vol.56 No.5 (5·î¹æ)¤Îɽ»æ¤ËÁª¤Ð¤ì¤Þ¤·¤¿¡£
2008ǯ3·î14Æü JBIC((¼Ò)¥Ð¥¤¥ª»º¶È¾ðÊó²½¥³¥ó¥½-¥·¥¢¥à)¤«¤é¤ÎFAMSBASE(¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¥Ç-¥¿¥Ù-¥¹)¸ø³«½ªÎ»¤Ë¤È¤â¤Ê¤¤¡¢¿Í¥²¥Î¥à¾å¤Ë¥³-¥É²½¤µ¤ì¤Æ¤¤¤ë¥¿¥ó¥Ñ¥¯¼Á¤Ë¤Ä¤¤¤ÆºÆ¥â¥Ç¥ê¥ó¥°¤·¤¿Human FAMSBASE(888,625¥â¥Ç¥ë)¤Î¾¦Éʲ½¤ò¸¡Æ¤¤·¤Æ¤ª¤ê¤Þ¤¹¡£
New Human FAMSBASE¤Ë´Ø¿´¤¬¤ªÍ­¤ê¤ÎÊý¤Ï¡¢¤ªÌ䤤¹ç¤ï¤»¥Õ¥©-¥à¤«¤é¤ªÌ䤤¹ç¤ï¤»¤¯¤À¤µ¤¤¡£
2008ǯ3·î5Æü ´ð½à¿¶Æ°²òÀÏË¡¤Ë¤è¤êClass I Major Histocompatibility Complex (MHC)ʬ»Ò¤Î»°¥É¥á¥¤¥ó¤ÎÁê¸ßºîÍÑÌò³ä¤ò²òÀϤ·¤¿ÏÀʸ¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£Chem.Pharm.Bull.,56(5),635-641 (2008) Dynamic interaction among the platform and two membrane-proiximal immunoglobulin-like domain of class I major histocompatibility complex: normal mode analysis
2008ǯ3·î1Æü ¸¶»Ò¥¿¥¤¥×¤È¸¶»Ò´Ö·ë¹çµ¬Â§¤ò´Þ¤à²½³Øµ­½Ò»Ò¤ò¥¿¡¼¥²¥Ã¥È¥¿¥ó¥Ñ¥¯¼Á¤Î£³¼¡¸µºÂɸ¤«¤éÃê½Ð¤·¤ÆºîÀ®¤µ¤ì¤¿²½¹çʪ»ØÌæ(Finger Print)¥»¥Ã¥È¤Ë¥Õ¥£¥Ã¥È¤¹¤ë²½¹çʪ¸ôÊä¤ò¥¤¥ó¥·¥ê¥³¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤¹¤ëÊýË¡ChooseLD¤ò³«È¯¤·¤Þ¤·¤¿¡£ÆÃ´ê2007-293751(11·î12Æü½Ð´ê); Chem.Pharm.Bull.,56(5),742-744 (2008) Bioinformatics based ligand-docking and in-silico screening
2008ǯ2·î1Æü CAPRI Round 6¡Á12¤ÎÀ®²Ì¤òProteins¤ËÅê¹Æ¤·¡¢ÏÀʸ¤Ë·ÇºÜ¤µ¤ì¤Þ¤·¤¿ CAPRI (the Critical Assessment of Predicted Interaction) ¤Ï¡¢¥¿¥ó¥Ñ¥¯¼Á-¥¿¥ó¥Ñ¥¯¼Á´Ö¥É¥Ã¥­¥ó¥°¹½Â¤Í½Â¬¹ñºÝ¥³¥ó¥Æ¥¹¥È¤Ç¤¹¡£
2007ǯ10·î1Æü CASP7¤ÎÀ®²Ì¤òProteins¤ËÅê¹Æ¤·¡¢ÏÀʸ¤Ë·ÇºÜ¤µ¤ì¤Þ¤·¤¿
2007ǯ9·î25Æü Þ¼¾å¶Õ»Ê¤¬Âåɽ¼èÄùÌò¤òÂàǤ¤·µ»½Ñ¸ÜÌä¤Ë¡¢¾®¾¾¹î°ìϺ¤¬Âåɽ¼èÄùÌò¤Ë½¢Ç¤¤·¤Þ¤·¤¿
2007ǯ5·î11Æü ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¼Ò¼çºÅ¤Î¹Ö±é²ñ(Ì£¤ÎÁdzô¼°²ñ¼Ò¥é¥¤¥Õ¥µ¥¤¥¨¥ó¥¹¸¦µæ½êÎëÌÚÜÆ°ìϺÍý»ö)¤È¿ÆËÓ²ñ¤ò¶äºÂ¤«¤Í¤Þ¤Ä¥Û¡¼¥ë¤Ç¹Ô¤¤¤Þ¤·¤¿¡£
2006ǯ12·î1Æü ¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬¥³¥ó¥Æ¥¹¥È(CASP7)¤ÇÀ¤³¦ºÇ¹â¥ì¥Ù¥ë¤ÎÀ®²Ì¡£¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÇß»³½¨ÌÀ¶µ¼ø¡ÊËÌΤÂç³Ø¡Ë¤¬¾·ÂÔ¹Ö±é
2006ǯ 9·î29Æü¡¡­ê¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤ÈÍý²½³Ø¸¦µæ½ê¤Î¶¦Æ±¸¦µæÀ®²Ì RIKEN FAMSBASE ¤Î¸ø³«¤Ë´Ø¤·¤Æ¡¢Æü·Ð¿·Ê¹¡¢Æü·Ð»º¶È¿·Ê¹¡Ê£¹Ì̡ˡ¢Æü´©¹©¶È¿·Ê¹¡Ê31ÌÌ¡Ë ¤Ë¾Ò ²ðµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2006ǯ 9·î28Æü¡¡­ê¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤ÈÍý²½³Ø¸¦µæ½ê¤Î¶¦Æ±¸¦µæÀ®²Ì RIKEN FAMSBASE ¤Î¸ø³«
2006ǯ 9·î7Æü¡¡Æü·Ð»º¶È¿·Ê¹¡¡1£´ÌÌ¡¡°åÎÅ¡¦¥Ð¥¤¥ª¡¡¥Ð¥¤¥ª¡Ö¤³¤ì¤Ç¹¶¤á¤ë¡×¤Ë­ê ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Î¾Ò²ðµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2006ǯ 6·î19Æü ³ô¼°²ñ¼Ò¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Ï¥¿¥«¥é¥Ð¥¤¥ª³ô¼°²ñ¼Ò¤ÈÈÎÇäÄó·È¤ò·ë¤Ó¡¢¶¦Æ±¤Ç¿·µ¬¥²¥Î¥à¾ðÊó¤ÎΩÂι½Â¤Í½Â¬¥µ¡¼¥Ó¥¹¤ò³«»Ï¤·¤Þ¤¹¡£
2006ǯ 6·î16Æü CASP7¤Ë¤ª¤¤¤Æ¡¢ËÌΤÂç³Ø¤ÎFAMS-MULTI¥Á¡¼¥à¤Î¥â¥Ç¥ë¤¬¹â¤¤É¾²Á¤ò¼õ¤±¡¢¡ÖÀºÌ©¤Ê¥â¥Ç¥ëºîÀ® (Targets Refinement)¡×¤Î¥³¥ó¥Æ¥¹¥È¤ÎÂêºà¤È¤·¤ÆÁª¤Ð¤ì¤Þ¤·¤¿¡£
2006ǯ 2·î18Æü ÆüËܷкѿ·Ê¹1Ì̤˥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹´ØÏ¢¤Îµ­»ö¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿¡£
2006ǯ 1·î20Æü Íý²½³Ø¸¦µæ½ê¤Ï¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î¥¿¥ó¥Ñ¥¯¼ÁÌóÀé6É´¼ïÎà¤Î¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¥â¥Ç¥ë¤ò̵½þ¤Ç¸ø³«¤·¤Þ¤·¤¿¡£
2005ǯ 12·î16Æü ËÌΤÂç³ØÌô³ØÉô ÃÝÅÄŽ°»ÖÂ뿿ͳ»Ò½õ¶µ¼ø((³ô)¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹ µ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼) 17ǯÅÙ ÆüËÜÌô³Ø²ñÌô³Ø¸¦µæ¥Ó¥¸¥ç¥óÉô²ñ¾Þ ¼õ¾Þ
2005ǯ 12·î1Æü ³ô¼°²ñ¼Ò¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÇß»³½¨ÌÀ¶µ¼ø¤Î¸¦µæ³è ư¤ò¾Ò²ð¤¹¤ëµ­»ö¤¬¡Ö¥á¥Ç¥£¥«¥ë¥É¥¥¡×»ï¤Ë·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2005ǯ 11·î22Æü¡¡SFC Entreprenuer Award 2005 Platinum Award¡Ê1°Ì¡Ë¼õ¾Þ
·Ä±þµÁ½ÎÂç³ØSFC Entrepreneur Award2004¤Ë¤Æ­ê¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹Âåɽ¼èÄùÌò¼ÒĹ¡¡Þ¼¾å¶Õ»Ê¤¬Platinum Award¡Ê1°Ì¡Ë¤ò¼õ¾Þ¡£SFC Entrepreneur Award¤Ï¡¢ÁÏΩ¤«¤éº£¤Þ¤Ç¿ô¿¤¯¤Îµ¯¶È²È¤òÇڽФ·¤Æ¤¤¤ëSFC¤ÎÎò»Ë¤òÇØ·Ê¤Ë¡¢·ÄØæµÁ½ÎÂç³Ø¤È²¿¤é¤«¤Î´Ø¤ï¤ê¤ò¤â¤Ã¤Æ¤¤¤ë(¤¢¤ë¤¤¤Ï´Ø¤ï¤ê»ý¤Ä¤³¤È¤ò´õ˾¤·¤Æ¤¤¤ë)µ¯¶È²È¤òȯ·¡¤·¡¢³×¿·Åª¤Êµ»½Ñ¡¦¥Î¥¦¥Ï¥¦¤ò³èÍѤ·¤Æ¡¢¿·¤·¤¤»Ô¾ì¤ò³«Â󤹤뤳¤È¤Ë¤è¤ê¡¢¼Ò²ñŪ¤Ê¹×¸¥¤ò¼Â¸½¤·¤è¤¦¤È¤¹¤ë¡¢µ¯¶È²ÈÀº¿À°î¤ì¤ë·Ð±Ä¼Ô¤òɽ¾´¤·¤Þ¤¹¡£
2005ǯ 8·î15Æü Æü·Ð¥Ð¥¤¥ª¥Ó¥¸¥Í¥¹¡¡2005ǯ£¹·î¹æ¡Ê2005.09 p60-65¡Ë¤Ë¡¢¡Ê³ô¡Ë¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¼Ò¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿¡£
2005ǯ 4·î 7Æü ËÌΤÂç³ØÌô³ØÉôÇß»³½¨ÌÀ¶µ¼ø¡ÊÍý²½³Ø¸¦µæ½êµÒ°÷¼ç´É¸¦µæ°÷¡¢¡Ê³ô¡Ë¥¤¥ó¥·¥ê¥³¥µ¥¤ ¥¨¥ó¥¹¤Î¸¦µæ¥¢¥É¥Ð¥¤¥¶¡¼¡Ë¤¬ÊüÁ÷Âç³ØÂç³Ø±¡¡Öʪ¼Á´Ä¶­²Ê³Ø­µ¡×¤ÎÂè12²ó¡Öʬ»Ò¤ÎΩÂι½Â¤¤ÈÀ¸Ì¿¡×¤ÈÂꤷ¤Æ¹ÖµÁ¤ò¤·¤Þ¤¹¡£º£Ç¯¡¢6·î27Æü¡Ê·î¡Ë¤Î14»þȾ¤«¤éÊü±Ç¤µ ¤ì¤ëͽÄê¤Ç¤¹¡£
2005ǯ 2·î17Æü¡¡Æü·Ð»º¶È¿·Ê¹21ÌÌ¡ÖÂç³ØVB¿Í¡ÁÃΤòÀ¸¤«¤¹¡Á¡×¤Ë¡¢¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÌô³ØÉô Çß»³½¨ÌÀ¶µ¼ø¤Ë´ØÏ¢¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£¤³¤Îµ­»ö¤Ç¤Ï¡¢Çß»³¶µ¼ø¤ÎÃÁÇò¼ÁΩÂι½Â¤¤Î¸¦µæ¶ÈÀӤȤ½¤³¤«¤éȯŸ¤·¤Æ³ô¼°²ñ¼Ò¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Î»ö¶È²½¤Ë»ê¤Ã¤¿·Ð°Þ¤¬¾Ò²ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
2004ǯ 12·î14Æü¡¡Æü·Ð¥Ð¥¤¥ª¥Æ¥¯¤Ë¡Ö¥¤ ¥ó ¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÃÝÅÄ- »ÖÂ뿿ͳ»Ò ËÌΤÂç³Ø½õ¶µ¼ø¾·ÂÔ¹Ö±é¡×¤Ë´ØÏ¢¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 12·î17Æü ¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬¥³¥ó¥Æ¥¹¥È¤ÇÀ¤³¦ºÇ¹â¥ì¥Ù¥ë¤ÎÀ®²Ì¡¢¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÃÝÅÄ-»ÖÂ뿿ͳ»Ò ËÌΤÂç³Ø½õ¶µ¼ø¾·ÂÔ¹Ö±é
2004ǯ 10·î 4Æü¡¡Ìî¼ëú·ô¤Î½µÊó ¡ÖÅ·´ã¶À¡×¡Ê10·î4Æü¹æ¡Ë¤Ë¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Î»ö¶È¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 9·î27Æü ÆüËܷкѿ·Ê¹¤Ë¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¥Ç-¥¿¥Ù-¥¹³«È¯(À¤³¦ºÇÂç)¤Ë´Ø¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 9·î 4Æü ÆüËܷкѿ·Ê¹¤ËSARS¼£ÎÅÌô¸ôÊä²½¹çʪȯ¸«¤Ë´Ø¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 6·î25Æü »°°æÊª»º³ô¼°²ñ¼Ò¤È¤Î·ÀÌóÄù·ë¤Ë¤Ä¤¤¤Æ
2004ǯ 6·î25Æü ÆüËܷкѿ·Ê¹(ͼ´©)£³Ì̤˥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤È»°°æÊª»º´ØÏ¢¤ÎÄó·È¤Ë´Ø¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 6·î 1Æü ¿·À½ÉʤÎȯÇä¤Î¤ªÃΤ餻¡£Éý¹­¤¤°åÌô¡¦À¸Ì¿²Ê³Ø¤Î¸¦µæ¼Ô¤ËÀ¤³¦ºÇ¹âÀºÅÙ¤ÎÃÁÇò¼ÁΩÂι½Â¤Í½Â¬¥½¥Õ¥È¤ò¼ê·Ú¤Ë»È¤Ã¤Æ¤¤¤¿¤À¤¯¤¿¤á¤Ë¡¢PDFAMS Pro ¤Ë Web User Interface µ¡Ç½¤òÅëºÜ¤·¤¿ PDFAMS Pro+ ÈÎÇä¤ò³«»Ï¤·¤Þ¤¹¡£
2004ǯ 3·î10Æü ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Î¡Ö¥²¥Î¥àÁÏÌô»Ù±ç¥·¥¹¥Æ¥à¤Î³«È¯¡×¥×¥í¥¸¥§¥¯¥È¤ÏÊ¿À®15ǯÅÙ¡Ö¸ø±×¿®Â÷¤ß¤º¤Û¥Ë¥å¡¼¥Ó¥¸¥Í¥¹°éÀ®´ð¶â¡×½õÀ®Àè9·ï¤ËÁª¤Ð¤ì ¤Þ¤·¤¿¡ÊÁí±þÊç¿ô210·ï¡Ë¡£ ( Æü´©¹©¶È¿·Ê¹¼Ò 2004ǯ3·î5Æü 21ÌÌ )
2004ǯ 3·î 1Æü Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹ Neuraminidase ¥â¥Ç¥ë²èÁü¤ò¸ø³«¤·¤Þ¤·¤¿
2004ǯ 1·î23Æü ÆüËܷкѿ·Ê¹17Ì̤˥³¥ó¥Ô¥å¡¼¥¿¡¼¥·¥ß¥å¥ì¡¼¥·¥ç¥ó´ØÏ¢¤Îµ­»ö¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 12·î25Æü Æü·Ð»º¶È¿·Ê¹1Ì̤ËPDFAMS´ØÏ¢¤Îµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿
2003ǯ 12·î 8Æü PDFAMS´ØÏ¢¤ÎÆüËÜSGIȯ¥×¥ì¥¹¥ê¥ê¡¼¥¹
2003ǯ 10·î29Æü JBICFAMSBASE¥µ¡¼¥Ó¥¹¤ÎNEWGPCR¥Ç¡¼¥¿¥Ù¡¼¥¹¤Ë³èÀ­·¿GPCR¥Ç¡¼¥¿¤òÄɲÃ
2003ǯ 10·î4Æü NHK¶µ°é¥Æ¥ì¥Ó¡ÖETV¥é¥¤¥Ö¥é¥ê¡¼¡×¡ÊºÆÊüÁ÷¡§10·î3Æü¶âÍËÆü¿¼Ìë2:15¡ÁÊüÁ÷ʬ¡Ë¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 10·î2Æü JBICFAMSBASE¥µ¡¼¥Ó¥¹¤ËNEWGPCR¥Ç¡¼¥¿¥Ù¡¼¥¹¤òÄɲÃ
2003ǯ 9·î10Æü À¾¥Ê¥¤¥ë¥¦¥¤¥ë¥¹Áý¿£´ØÏ¢ÃÁÇò¼Á¥â¥Ç¥ë²èÁü¤ò¸ø³«¤·¤Þ¤·¤¿
2003ǯ 9·î 9Æü NHK¥Ë¥å¡¼¥¹10(9·î9Æü22»þ¡Á)¤Ç½Å¾ÉµÞÀ­¸ÆµÛ´ï¾É¸õ·²¡ÊSARS)¤Î´µ¼Ô¤¬¥·¥ó¥¬¥Ý¡¼¥ë¤ÇȯÀ¸¤·¤¿¤È¤Î¥Ë¥å¡¼¥¹¤¬Êü±Ç¤µ¤ì¤Þ¤·¤¿
2003ǯ 9·î 9Æü NHK¥Ë¥å¡¼¥¹10(9·î9Æü22»þ¡Á)¤ÇSARS¥×¥í¥Æ¥¢¡¼¥¼¤Ë·ë¹ç¤¹¤ë°åÌôÉʤª¤è¤Ó¥ê¥¬¥ó¥É´ØÏ¢¤Î¥Ë¥å¡¼¥¹¤¬Êü±Ç¤µ¤ì¤Þ¤·¤¿
2003ǯ 9·î 9Æü NHK¥Ë¥å¡¼¥¹(9·î9Æü7»þ¡Á)¤Ç°¦É²Âç³Ø¤Ë¤Æ¾®Çþæõ²ê¤ò»È¤Ã¤Æ¥»¥ë¥Õ¥ê¡¼¤Î¾õÂÖ¤ÇSARS¥×¥í¥Æ¥¢¡¼¥¼¤ò¿Í¹©¹çÀ®¤¹¤ë¤³¤È¤ËÀ®¸ù¤Î¥Ë¥å¡¼¥¹¤¬Êü±Ç¤µ¤ì¤Þ¤·¤¿
2003ǯ 9·î 6Æü SARS¥×¥í¥Æ¥¢¡¼¥¼¤Ë·ë¹ç¤¹¤ë°åÌôÉʤª¤è¤Ó¥ê¥¬¥ó¥É¥é¥ó¥­¥ó¥°É½¤ò¸ø³«¤·¤Þ¤·¤¿
2003ǯ 9·î 2Æü ÆüËܷкѿ·Ê¹¤ËSARS¿·Ìô´ØÏ¢µ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿
2003ǯ 8·î31Æü ¿ÀÆàÀʹ¤ËËÌΤÂç³ØÇß»³½¨ÌÀ¶µ¼ø¡Ê¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹µ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¡Ë¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 8·î19Æü ¥Ú¥×¥Á¥ÉÇÛÎ󤫤é¤Î¹½Â¤¸¡º÷¥µ¡¼¥Ó¥¹¤ò³«»Ï¤·¤Þ¤·¤¿
2003ǯ 7·î26Æü PDB(Protein Data Bank)¤Ë¤ÆXÀþ²òÀϤˤè¤ëSARS¹½Â¤¥Ç¡¼¥¿¤¬¸ø³«¤µ¤ì¤Þ¤·¤¿
2003ǯ 7·î25Æü NHK¶µ°é¥Æ¥ì¥Ó¥µ¥¤¥¨¥ó¥¹ZERO¡ÊÁí½¸ÊÔ¡§7·î29Æü²ÐÍËÆü¿¼Ìë0»þ¡ÁÊüÁ÷ʬ¡Ë¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 7·î23Æü ¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Í­½þÄó¶¡¥µ¡¼¥Ó¥¹¤ò³«»Ï¤¤¤¿¤·¤Þ¤·¤¿
2003ǯ 7·î18Æü JBICFAMSBASE¥µ¡¼¥Ó¥¹¤Ë´Ø¤¹¤ëÆüËÜSGIȯ¥×¥ì¥¹¥ê¥ê¡¼¥¹
2003ǯ 7·î18Æü JBICFAMSBASE¥µ¡¼¥Ó¥¹¤ËGPCR¥Ç¡¼¥¿¥Ù¡¼¥¹¤òÄɲÃ
2003ǯ 7·î17Æü SARS Proteinase¥â¥Ç¥ë¤ËHIV¥×¥í¥Æ¥¢¡¼¥¼Á˳²ºÞNelfinavir¡Ê1OHR¡Ë¤ò¥É¥Ã¥­¥ó¥°¤·¤¿¥â¥Ç¥ë¹½Â¤¤Î¸ø³«³«»Ï
2003ǯ 7·î15Æü Åìµþ°å²Ê»õ²ÊÂç¤ÈµþÅÔÂç¤Ê¤É¤Î¥°¥ë¡¼¥×¡¢¥¨¥¤¥º¤Î¼£ÎÅÌôNelfinavir¤¬SARSÍÞÀ©¸ú²Ì¤¬¤¢¤ë¤³¤È¤òȯɽ
2003ǯ 6·î17Æü NHK¶µ°é¥Æ¥ì¥Ó¥µ¥¤¥¨¥ó¥¹ZERO¡ÊSARSÆÃ½¸¡§7·î8Æü²ÐÍËÆü¿¼Ìë0»þ¡ÁÊüÁ÷ʬ¡Ë¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 6·î15Æü Æü·Ð¥Ð¥¤¥ª¥Ó¥¸¥Í¥¹7·î¹æ¤ËSARS¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬´ØÏ¢¤Îµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿
2003ǯ 6·î11Æü SARS¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Ìµ½þÄó¶¡¥µ¡¼¥Ó¥¹¤Ë´Ø¤¹¤ëÊÆ¹ñSGIȯ¥×¥ì¥¹¥ê¥ê¡¼¥¹
2003ǯ 6·î 4Æü JBiC¤ÎWeb¥µ¥¤¥È¤Ë¤ª¤¤¤ÆFAMSBASE¤ÎÄ󶡤ò³«»Ï
2003ǯ 5·î30Æü ¥«¥Ê¥ÀNew BrunswickÂç³Ø¡¢Í½Â¬¤·¤¿SARS¥¦¥¤¥ë¥¹Protease¹½Â¤¤ò¸ø³«
2003ǯ 5·î18Æü Ãæ¹ñ¥°¥ë¡¼¥×¡¢SARS¥³¥í¥Ê¥¦¥¤¥ë¥¹Protease¹½Â¤¤È¥Ç¥¶¥¤¥ó¤·¤¿Á˳²ºÞ¤ò¸ø³«
2003ǯ 5·î16Æü Eidogen¼Ò¡¢SARS¥¦¥¤¥ë¥¹¤ÎÃÁÇò¼Áʬ²ò¹ÚÁǤÎΩÂι½Â¤¤ò¸øÅª¥Ç¡¼¥¿¥Ð¥ó¥¯¤Ë´óÂ÷
2003ǯ 5·î13Æü ÆÈ¥°¥ë¡¼¥×¡¢SARS protease¤Î¹½Â¤¤òÊÆ¥µ¥¤¥¨¥ó¥¹¡ÊÅÅ»ÒÈǡˤËȯɽ
2003ǯ 5·î12Æü SARS¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Ìµ½þÄó¶¡¥µ¡¼¥Ó¥¹¤Ë´Ø¤¹¤ëÆüËÜSGIȯ¥×¥ì¥¹¥ê¥ê¡¼¥¹
2003ǯ 5·î 9Æü SARS¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Ìµ½þÄó¶¡¥µ¡¼¥Ó¥¹¤ò³«»Ï
2002ǯ11·î26Æü ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¼ÒÀßΩ


Copyright (C) 2003 In-Silico Sciences Inc. All Rights Reserved